In Vitro Lung Model Market is expected to reach US$ 1,530.11 Million by 2031

3D Models Segment Bolsters  In Vitro Lung Model Market Growth 

According to our new research study on "In Vitro Lung Model Market Forecast to 2031 – Global Analysis – by Type, Application, End User", the market was valued at US$ 446.35 million in 2024 and is projected to reach US$ 1,530.11 million by 2031; it is estimated to register a CAGR of 19.4% during 2025–2031. The In Vitro Lung Model Market report emphasizes the trends prevalent in the global market, along with drivers and deterrents affecting its growth. 

The surging prevalence of respiratory diseases and rising adoption of in vitro models as an alternative to animal testing contribute to the growing In Vitro Lung Model Market size. However, the high cost associated with vaccines hampers the growth of the market. Further, technological advancements in veterinary vaccine products are expected to bring new In Vitro Lung Model Market trends in the coming years.

In Vitro Lung Model Market Share, by Technology, 2024 (%)

Source: The Insight Partners Analysis

Surging Prevalence of Respiratory Diseases Bolsters In Vitro Lung Model Market Growth

According to a report published by the Global Initiative on Chronic Obstructive Lung Disease, ~65 million people suffer from obstructive pulmonary disease (COPD), and nearly 3 million people die from the disease each year, making it the fourth leading cause of mortality worldwide. According to the 2023 American Lung Association data, ~34 million Americans were affected by chronic lung diseases such as asthma and COPD. In 2022, ~11.7 million adults, or 4.6% of the population in the US, were diagnosed with COPD. As per an article published in the European Respiratory Journal in 2020, 36.58 million Europeans were reported to have COPD, which is projected to reach 49.45 million by 2050, representing a 35.2% relative increase. With the growing prevalence of smoking in developing countries and the aging population in high-income countries, the COPD prevalence is projected to rise over the next forty years. As per the World Health Organization (WHO) estimates, COPD will become one of the leading causes of death worldwide by 2030, and it is estimated that by 2060, there will be more than 5.4 million deaths yearly due to COPD and related conditions.

This rising incidence of respiratory diseases is spurring the demand for advanced research models to understand disease mechanisms and develop effective treatments. In vitro lung models provide valuable platforms for studying disease mechanisms and testing potential therapies, supporting the development of effective treatments. Additionally, lung organoids and bioengineered organs-on-chips—both examples of three-dimensional (3D) cell culture models—are valuable tools in respiratory disease research. These models have been used to study how the lung responds to infections by influenza A and coronaviruses through the lung airways, small airways, and alveoli organ chips.

The University of Michigan's "lung-on-a-chip" device uses human lung-tissue cells cultured on a plastic chip with microscopic channels to simulate the conditions inside the lungs, providing new insights into diseases. Thus, the increasing demand for effective treatments and research models fuels the in vitro lung model market growth.

The In Vitro Lung Model Market analysis has been carried out by considering the following segments: type, application, end user, and geography. Based on type, the market is divided into 3D Models and 2D Models. The 3D Models segment held the largest In Vitro Lung Model Market share in 2024, and it is expected to register the highest CAGR during 2024–2031.

3D lung models replicate the complex architecture and cellular interactions of human lung tissue accurately. The enhanced physiological relevance makes them invaluable for drug discovery, toxicity testing, and disease modeling. The primary types of 3D lung models include spheroids, organoids, and precision-cut lung slices (PCLS). In 3D models, cells are cultured within a three-dimensional structure, offering advantages over traditional 2D models. These models closely replicate the architecture and microenvironment of the lung, enabling accurate simulation of physiological conditions. As a result, drug and therapeutic studies using 3D models tend to yield more accurate and reliable results than those derived from 2D models or animal models.   

By application, In Vitro Lung Model market is segmented into drug discovery and toxicology studies, physiological research, regenerative medicine, and others. The drug discovery and toxicology studies segment held the largest share of the in vitro lung model market in 2024. The rising incidence of asthma, COPD, and lung cancer has heightened the demand for effective treatment options. According to Asthma Epidemiology, more than 300 million individuals currently have asthma, and the prevalence continues to rise every year, mostly in low and middle-income countries. Nearly 250,000 individuals succumb to the disease yearly. The rising air pollution levels, growing tobacco consumption, and an aging population are contributing to the increasing burden of respiratory illnesses. In vitro lung models provide a highly controlled and efficient platform for drug screening, which helps pharmaceutical companies and researchers develop potential drugs to tackle these diseases.

Cell lines such as A549 and Calu-3, as well as organ-on-a-chip and precision-cut lung slices (PCLS), provide researchers with tools to simulate human lung physiology and pathology. These models facilitate the evaluation of drug efficacy and toxicity, offering insights into how therapeutic agents interact with lung tissues. For example, studies have demonstrated that PCLS can be used to assess airway constriction and bronchodilation in response to compounds, aiding in the development of treatments for asthma. These models facilitate the development and testing of new therapies by providing a controlled environment to study disease mechanisms and drug responses. In vitro lung models have utility for investigating multiple aspects of pulmonary toxicology. The recently developed microfluidics-based models for lungs support high-throughput screening and allow early-stage toxicology testing in human systems that facilitate the development of innovative medical products.

Per end user, In Vitro Lung Model market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, and others. The pharmaceutical and biotechnology companies segment held the largest share of the In Vitro lung model market in 2024.

The geographic scope of the In Vitro Lung Model Market report includes the assessment of the market performance in North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America. North America is expected to dominate the market in 2024. The In Vitro Lung Model Market in North America is segmented into the US, Canada, and Mexico. The US holds the largest market share, followed by Canada. In North America, the US boasts a strong biomedical research infrastructure. The region is home to leading academic institutions, research organizations, and pharmaceutical companies that are at the forefront of in vitro lung modeling research. These institutions have access to state-of-the-art facilities, cutting-edge technologies, and skilled researchers, enabling them to innovate and advance the field. The market growth is also fueled by the presence of major industry players, the expansion of animal welfare programs and regulations, and a well-established healthcare infrastructure. Also, favorable government initiatives and a rising number of research collaborations boost growth further. Supportive healthcare policies, substantial investments in product development, stringent animal welfare laws, and increased awareness campaigns also contribute to the advancement of the market within a mature healthcare environment.

Key developments in the In Vitro Lung Model Market are mentioned below:

• In September 2024, MatTek Life Sciences, a biotech company specializing in the development of in vitro human tissues, announced the licensing of its organotypic human tissues to CellEx, a life science laboratory based in China. This strategic collaboration marks a milestone in the advancement and utilization of human tissues for research, pharmaceutical development, and safety assessment applications.
• In June 2023, Emulate, Inc., a provider of next-generation in vitro models, announced the launch of the Emulate Chip-A1 Accessible Chip through an early access program. This new Organ-Chip design expands on the original Chip-S1—which models tissue-vascular interfaces with relevant biomechanical forces such as stretch and flow—by allowing users to create thicker tissues within the epithelial culture chamber and apply additional drug treatment options, including topical or aerosolized applications.

Contact Us

Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com